Immunovant, Inc. Common Stock vs. Kymera Therapeutics, Inc. Common Stock
IMVT
Immunovant, Inc. Common Stock
$41.82 +0.00%
VS KYMRKymera Therapeutics, Inc. Common Stock
$117.39 +2.60%
Kymera Therapeutics, Inc. Common Stock (KYMR) comes out ahead, leading on 4 of 5 compared factors.
Size & Scale
| IMVT | KYMR | |
|---|---|---|
| Market Cap | $8.80 billion | $9.48 billion |
| Revenue (TTM) | — | $105.00 million |
| Net Income (TTM) | $-538,217,000 | $-299,601,000 |
KYMR leads on 2 of 2 size & scale factors.
Valuation
| IMVT | KYMR | |
|---|---|---|
| Price / Book | 11.97 | 6.28 |
| Price / Sales | — | 90.30 |
KYMR leads on 1 of 1 valuation factors.
Profitability
| IMVT | KYMR | |
|---|---|---|
| Net Margin | — | -285.34% |
| Return on Equity | -73.19% | -19.85% |
KYMR leads on 1 of 1 profitability factors.
Risk & Sentiment
| IMVT | KYMR | |
|---|---|---|
| Short Interest | 0.15% | 0.24% |
IMVT leads on 1 of 1 risk & sentiment factors.
Dig deeper: IMVT overview, IMVT financials, KYMR overview, KYMR financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.